AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04043923
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT05914896
Drug: HighOsmo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group received a priming solution with high osmolality
Trial: NCT02884297
Drug: Contrast agent: SonoVue®.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SonoVue® Injection: will be done through the peripheral venous way already set up by the anesthetist for its injection. None venous dedicated way will be established. The injection will take place when the woman will be under general anesthesia, ventilated and under constant cardio-respiratory monitoring.
Trial: NCT00253968
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT00004831
Drug: cysteine hydrochloride
RxNorm normalized name: Cysteine Hydrochloride
DrugBank: Cysteine (DB00151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02414269
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive cyclophosphamide intravenously (at 1.5 g/m\^2)
Trial: NCT04233476
Drug: 99mTc-3PRGD2 injection
RxNorm normalized name: Technetium (99mTc), particles for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A diagnostic drug targeting integrin αvβ3, technetium-99m \[99mTc\] labeled hydrazinonicotinamide-PEG4-E\[PEG4-c(RGDfk)\]2 (99mTc-3PRGD2), will be intravenously injected to the participants for imaging of lung cancer and mapping lymph node metastasis via single photon emission computed tomography/ X-ray computed tomography (SPECT/CT) .
Trial: NCT01845740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered subcutaneously once weekly for 4 weeks.
Trial: NCT02639260
Drug: N-acetyl D-mannosamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose escalation
Trial: NCT00728936
Drug: IMO-2125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMO-2125 is a synthetic DNA-based agonist of Toll-like receptor 9 (TLR9), TLR9 is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system
Trial: NCT00728936
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline placebo given subcutaneously
Trial: NCT00430794
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03493191
Drug: 0.5μg/kg SHR0410
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single dose of 0.5μg/kg SHR0410
Trial: NCT03493191
Drug: 1μg/kg SHR0410
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single dose of 2μg/kg SHR0410
Trial: NCT03493191
Drug: 2μg/kg SHR0410
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single dose of 2μg/kg SHR0410
Trial: NCT03493191
Drug: 5μg/kg SHR0410
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single dose of 5μg/kg SHR0410
Trial: NCT03493191
Drug: 10μg/kg SHR0410
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single dose of 10μg/kg SHR0410
Trial: NCT03493191
Drug: 20μg/kg SHR0410
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single dose of 20μg/kg SHR0410
Trial: NCT01334229
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 6 weeks
Trial: NCT02911818
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01943188
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02934152
Drug: H pylori eradication
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H pylori eradication
Trial: NCT03498092
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline in a volume of 0.5 ml/kg
Trial: NCT02320240
Drug: Desvenlafaxine
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Current exposure to Desvenlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
Trial: NCT01734759
Drug: Taste Test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before the taste test each participant will fill out an informed consent form and an enrollment survey. Each participant will receive 0.5 mL of each study medication in the taste test. During the taste test each medication in a class will be labeled with a color name so as to prevent any bias from preconceived taste perception. They will record their perception of the medications taste on a visual analog scale (VAS). An anaphlyaxis kit will be on hand in case of emergencies. Between samples participants will cleanse their palate with a saltine cracker and 30 mL of water. 5 different classes of medications will be tested.~Medications to be sampled and the corresponding dose of the test dose are:~* Cephalosporins: cefdinir 12.5 mg, cefixime 10 mg~* Penicillins: penicillin VK 12.5 mg, amoxicillin 12.5 mg~* Analgesic/antipyretics: acetaminophen 16 mg, ibuprofen 10 mg~* Steroids: prednisolone 1.5 mg, prednisone 0.5 mg~* H2 receptor blockers: famotidine 4 mg, ranitidine 7.5 mg
Trial: NCT02320240
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Current exposure to Fluoxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
Trial: NCT04404712
Drug: [11C]MK-3168
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One PET scan involving administration of PET ligand \[11C\]MK-3168
Trial: NCT02308748
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (#2 Gelcap or IV saline)
Trial: NCT03588026
Drug: rVA576
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months of treatment, rVA576 plus SOC. Followed by a further 3 months of rVA576 plus SOC. In total, 9 months on rVA576 plus SOC.
Trial: NCT00558311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered by continuous infusion matching clazosentan administration
Trial: NCT01346748
Drug: statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinvastatin 80 mg per day - 21 days versus placebo
Trial: NCT00003532
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Stage III or IV Ovarian Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT02429765
Drug: ACL/FOR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01489995
Drug: A (migalastat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg migalastat HCl in the fasting state (reference arm)
Trial: NCT01489995
Drug: B (migalastat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg migalastat HCl with simultaneous consumption of a glucose drink
Trial: NCT01489995
Drug: E (migalastat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg migalastat HCl 1 hour after consumption of a light meal
Trial: NCT04270214
Drug: Dysport Injectable Product
RxNorm normalized name: Dysport Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dysport injections optimized using kinematics
Trial: NCT01800968
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02136641
Drug: Midazolam+Fentanyl Combination
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Was applied Midazolam 0.015 mg / Kg + Fentanyl 0.8mcg/kg, IV (in the vein), single dose.
Trial: NCT01215292
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 gm of 1% T Gel applied transdermally for 10 days
Trial: NCT00403416
Drug: AEB071
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00403416
Drug: Mycophenolic Acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02251990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet matching grazoprevir/elbasvir FDC tablet taken q.d. by mouth for 12 weeks.
Trial: NCT00570063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days.
Trial: NCT01395381
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo given once
Trial: NCT00274638
Drug: Telmisartan & Hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04169308
Drug: Restylane-L® Filler injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restylane-L® Filler injection into the soft tissue of the nose
Trial: NCT00540124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once a day
Trial: NCT02763800
Drug: BIA 3-202
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 3-202 (50, 100 and 200 mg) was administered in the form of oral tablets, given with 200 ml potable water.
Trial: NCT02763800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo was administered in the form of oral tablets, given with 200 ml potable water
Trial: NCT02451527
Drug: PEX168
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEX168 in subcutaneous injection on Day8，15，22，29 and Day 36
Trial: NCT01939548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID until the Week 12 visit
Trial: NCT00700921
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg po once daily
Trial: NCT00700921
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule, once daily
Trial: NCT03493048
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: leucovorin 200 mg/m²
Trial: NCT04204629
Drug: HIP1601 40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dosing of HIP1601 40mg, PO
Trial: NCT00293150
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00877006
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00877006
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01773070
Drug: ABT-333
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug is not administered -- this study is follow-up for participants previously receiving the drug.
Trial: NCT01773070
Drug: ABT-267
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug is not administered -- this study is follow-up for participants previously receiving the drug.
Trial: NCT01993225
Drug: Androxal 12.5 mg/25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01993225
Drug: Placebo Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01993225
Drug: AndroGel 1.62%
RxNorm normalized name: Androgel 1.62% Transdermal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01993225
Drug: Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02265302
Drug: BIIL 284 oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02265302
Drug: BIIL 284 wetability improved formulation (WIF) tablets
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02265302
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02203474
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05506787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02795273
Drug: Grass-SPIRE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02795273
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03978234
Drug: AbobotulinumtoxinA 300 UNT
RxNorm normalized name: abobotulinumtoxinA 300 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AbobotulinumtoxinA 300 UNT
Trial: NCT01970462
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively
Trial: NCT01639456
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Infused intravenously 60 mg/kg x day -5
Trial: NCT02144064
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group A (n = 100) are put on Inj. UFH (Cal-heparin) 5000 U subcutaneous twice daily plusAspirin 81 mg/day (Juspirin) with the ﬁrst positive pregnancy test, Inj. UFH is given either into anterior abdominal wall or anterior aspect of thigh subcutaneously
Trial: NCT03311412
Drug: Sym021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.
Trial: NCT03311412
Drug: Sym023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.
Trial: NCT03728504
Drug: ASN002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of ASN002 for 32 weeks
Trial: NCT03728504
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of Placebo Oral Tablet for 16 weeks
Trial: NCT04209530
Drug: EN3835
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagenase Clostridium Histolyticum (CCH)
Trial: NCT00894231
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar tablet
Trial: NCT02633137
Drug: R-CHOP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Rituximab 375 mg/m\^2 IVPB with premedications Day 1~* Cyclophosphamide 750 mg/m\^2 IVPB Day 1~* Doxorubicin 50 mg/m\^2 IVP Day 1~* Vincristine 1.4 mg/m\^2 IVP (capped at 2 mg) Day 1~* Prednisone 100 mg PO Daily on Days 1-5 or 2-6
Trial: NCT04495179
Drug: AZD4635
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive AZD4635 orally daily
Trial: NCT03731689
Drug: Intrauterine lavage therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrauterine lavage treatment was performed within 3 to 7 days after the first menstrual period after surgery.
Trial: NCT00449176
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo twice daily for 15 weeks
Trial: NCT00594867
Drug: Acetaminophen - 4 grams per day + Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen - 4 grams per day + Placebo
Trial: NCT00594867
Drug: Acetaminophen 4 gram per day + Aspirin 325 mg per day
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 4 gram per day + Aspirin 325 mg per day
Trial: NCT02217930
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02540824
Drug: Apatinib single agent arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For RET-fusion positive advanced NSCLC patients who failed to previous treatment,treat with apatinib, single agent, 750mg once daily, p.o until disease progression
Trial: NCT00244296
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01749982
Drug: Choline bitartrate
RxNorm normalized name: Choline Bitartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01749982
Drug: Choline bitartrate + Betaine
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03392714
Drug: R-B(O)AD
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rituximab 375 mg/m2 on day 1; vincristine 1.4 mg/m2 on day 1, omitted in patients ≥70 years of age due to risk of neurotoxicity; bendamustine 75 mg/m2 over 1 h on days 2 and 3; cytarabine 1000 mg/m2 over 3 h on days 2-4; dexamethasone 20 mg on days 1-4, administered intravenously
Trial: NCT03579030
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule matched to an RTA 1701 capsule
Trial: NCT02685657
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02685657
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02679261
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration placebo
Trial: NCT01239030
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT00434382
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00434382
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00434382
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00859079
Drug: Human regular insulin intravenously
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human regular insulin intravenously according to the Munich-registry.
Trial: NCT00683644
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc taken once daily
Trial: NCT00683644
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules taken once daily
Trial: NCT00141154
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00141154
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00410033
Drug: soluble human insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00410033
Drug: isophane human insulin
RxNorm normalized name: insulin isophane, human
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03215797
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine 5ug/ml IV infusion at a rate of 5 ml/h in case of hypotension
Trial: NCT00114010
Drug: AMA1/Alhydrogel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04653766
Drug: Ir-CPI - Dose 2
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 participants received a single intravenous dose of 3.0 mg/kg of Ir-CPI during 6 hours
Trial: NCT04653766
Drug: Ir-CPI - Dose 4
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 participants received a single intravenous dose of 9.0 mg/kg of Ir-CPI during 6 hours
Trial: NCT04653766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each dose group, 2 additional participants received a single intravenous dose of placebo during 6 hours (8 in total).
Trial: NCT00575926
Drug: LingZhi capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LingZhi or Placebo 300 mg x 4 or 300 mg x 6 capsules daily according to age group
Trial: NCT03088826
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg Acetaminophen
Trial: NCT01527734
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1ml once or twice a day for 1 or 2 days.
Trial: NCT03230708
Drug: convention drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: according to usage method of drugs
Trial: NCT00093834
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination
Trial: NCT00093834
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination